Malta - English - Medicines Authority

accord healthcare limited - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; microcrystalline cellulose; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 400 - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; sodium starch glycollate; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of postmenopausal women with hormone receptor positive breast cancer (see "clinical trials"). the safety and efficacy of neoadjuvant use has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; hypromellose; lactose monohydrate; magnesium stearate; hyprolose; iron oxide yellow; macrogol 8000; microcrystalline cellulose; titanium dioxide - treatment of postmenopausal women with hormone receptor positive early breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Canada - English - Health Canada

jamp pharma corporation - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries limited - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg